IAXO-102

IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development[1].

Product Specifications

CAS Number

[1115270-63-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/IAXO-102.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 50 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCO[C@@H]1[C@H]([C@@H]([C@@H](CN)O[C@@H]1OC)O)OCCCCCCCCCCCCCC

Molecular Formula

C35H71NO5

Molecular Weight

585.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Huggins C, et al. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development. Atherosclerosis. 2015 Oct;242 (2) :563-70.